Jefferies Group Reiterates Buy on Questcor Pharmaceuticals (QCOR)

By admin | 6 years ago

Questcor Pharmaceuticals (NASDAQ: QCOR)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group (NYSE: JEF) in a report issued on Monday.

Shares of Questcor Pharmaceuticals opened at 39.97 on Monday. Questcor Pharmaceuticals has a one year low of $19.26 and a one year high of $45.95. The company has a market cap of $2.538 billion and a P/E ratio of 24.69.

Questcor Pharmaceuticals last issued its quarterly earnings data on Wednesday, February 22nd. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.06. The company’s revenue for the quarter was up 157.7% on a year-over-year basis. On average, analysts predict that Questcor Pharmaceuticals will post $0.59 earnings per share next quarter.

QCOR has been the subject of a number of other recent research reports. Analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of Questcor Pharmaceuticals in a research note to investors on Thursday, April 19th. They set an “overweight” rating on the stock. Separately, analysts at Roth Capital initiated coverage on shares of Questcor Pharmaceuticals in a research note to investors on Wednesday, April 11st. They set a “buy” rating on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Questcor Pharmaceuticals from $49.00 to $50.00 in a research note to investors on Monday, April 9th.

Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. Questcor primary product is H.

About the author